X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Divis Laboratories with Glenmark Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DIVIS LABORATORIES vs GLENMARK PHARMA - Comparison Results

DIVIS LABORATORIES    Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

GLENMARK PHARMA 
   Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DIVIS LABORATORIES GLENMARK PHARMA DIVIS LABORATORIES/
GLENMARK PHARMA
 
P/E (TTM) x 18.3 13.6 134.0% View Chart
P/BV x 4.0 3.8 103.5% View Chart
Dividend Yield % 1.6 0.3 470.6%  

Financials

 DIVIS LABORATORIES   GLENMARK PHARMA
EQUITY SHARE DATA
    DIVIS LABORATORIES
Mar-16
GLENMARK PHARMA
Mar-16
DIVIS LABORATORIES/
GLENMARK PHARMA
5-Yr Chart
Click to enlarge
High Rs2,4841,262 196.8%   
Low Rs918672 136.7%   
Sales per share (Unadj.) Rs142.3270.6 52.6%  
Earnings per share (Unadj.) Rs41.924.9 168.4%  
Cash flow per share (Unadj.) Rs46.334.4 134.6%  
Dividends per share (Unadj.) Rs10.002.00 500.0%  
Dividend yield (eoy) %0.60.2 284.2%  
Book value per share (Unadj.) Rs161.5151.3 106.7%  
Shares outstanding (eoy) m265.47282.16 94.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x12.03.6 334.6%   
Avg P/E ratio x40.638.9 104.5%  
P/CF ratio (eoy) x36.728.1 130.7%  
Price / Book Value ratio x10.56.4 164.9%  
Dividend payout %23.98.0 297.0%   
Avg Mkt Cap Rs m451,525272,778 165.5%   
No. of employees `0003.710.0 37.0%   
Total wages/salary Rs m3,64913,782 26.5%   
Avg. sales/employee Rs Th10,184.47,614.9 133.7%   
Avg. wages/employee Rs Th984.11,374.8 71.6%   
Avg. net profit/employee Rs Th2,998.5700.2 428.3%   
INCOME DATA
Net Sales Rs m37,76476,340 49.5%  
Other income Rs m848356 238.2%   
Total revenues Rs m38,61276,696 50.3%   
Gross profit Rs m14,13814,172 99.8%  
Depreciation Rs m1,1822,691 43.9%   
Interest Rs m231,789 1.3%   
Profit before tax Rs m13,78110,048 137.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,6623,028 87.9%   
Profit after tax Rs m11,1197,019 158.4%  
Gross profit margin %37.418.6 201.7%  
Effective tax rate %19.330.1 64.1%   
Net profit margin %29.49.2 320.2%  
BALANCE SHEET DATA
Current assets Rs m30,94759,096 52.4%   
Current liabilities Rs m5,19540,018 13.0%   
Net working cap to sales %68.225.0 272.9%  
Current ratio x6.01.5 403.4%  
Inventory Days Days11775 155.7%  
Debtors Days Days85119 71.4%  
Net fixed assets Rs m17,02739,075 43.6%   
Share capital Rs m531282 188.1%   
"Free" reserves Rs m42,34130,281 139.8%   
Net worth Rs m42,87742,703 100.4%   
Long term debt Rs m524,873 0.0%   
Total assets Rs m49,684111,026 44.8%  
Interest coverage x595.06.6 8,992.6%   
Debt to equity ratio x00.6 0.0%  
Sales to assets ratio x0.80.7 110.5%   
Return on assets %22.47.9 282.7%  
Return on equity %25.916.4 157.8%  
Return on capital %32.217.5 183.8%  
Exports to sales %85.343.3 197.0%   
Imports to sales %22.97.4 308.4%   
Exports (fob) Rs m32,19833,044 97.4%   
Imports (cif) Rs m8,6545,672 152.6%   
Fx inflow Rs m32,27036,945 87.3%   
Fx outflow Rs m8,77561,066 14.4%   
Net fx Rs m23,496-24,122 -97.4%   
CASH FLOW
From Operations Rs m10,3793,449 301.0%  
From Investments Rs m-4,135-8,802 47.0%  
From Financial Activity Rs m-6,2416,986 -89.3%  
Net Cashflow Rs m3934 0.4%  

Share Holding

Indian Promoters % 52.0 48.3 107.7%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 11.8 6.9 171.0%  
FIIs % 19.0 34.4 55.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.2 10.5 163.8%  
Shareholders   31,796 56,727 56.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DIVIS LABORATORIES With:   DR. DATSONS LABS  STRIDES SHASUN LTD  FULFORD INDIA  JUBILANT LIFE SCIENCES  BIOCON LTD  

Compare DIVIS LABORATORIES With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Finishes on a Strong Note; Bank & Realty Stocks Rally(Closing)

Indian share markets surged further in the afternoon session and finished in the green for the second straight session on heavy buying in realty stocks, metal stocks and bank stocks.

Related Views on News

Glenmark Pharma: Lower Zetia Sales leads to Subdued Growth (Quarterly Results Update - Detailed)

May 18, 2017

Base price erosion in the US and lower Zetia sales impacts profits.

Glenmark: Zetia Generics Boost Growth (Quarterly Results Update - Detailed)

Feb 15, 2017

Glenmark has announced its 3QFY16 results. The company has reported 41% YoY growth in net sales and 143.2% YoY increase in net profits. Here is our analysis of the results.

Glenmark: High Costs hit the Bottom line (Quarterly Results Update - Detailed)

Nov 8, 2016

Glenmark has announced its 2QFY16 results. The company has reported 15.7% YoY growth in net sales and 3.5% YoY increase in net profits. Here is our analysis of the results.

Glenmark: Other Income Boosts Profit Growth (Quarterly Results Update - Detailed)

Sep 6, 2016

Glenmark has announced its 1QFY17 results. The company has reported 15.8% YoY growth in net sales and 24% YoY increase in net profits. Here is our analysis of the results.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

More Views on News

Most Popular

This Small Cap Can Drive Chinese Players Out of India (and Make a Fortune in the Process)(The 5 Minute Wrapup)

Aug 17, 2017

A small-cap Indian company with high-return potential and blue-chip-like stability is set to supplant the Chinese players in this niche segment.

The Most Important Innovation in Finance Since Gold Coins(Vivek Kaul's Diary)

Aug 10, 2017

Bill connects the dots...between money and growth, real money and real resources, gold and cryptocurrencies...and between gold, cryptocurrencies, and time.

It's the Best Time to Buy IT Stocks(Daily Profit Hunter)

Aug 16, 2017

The IT Sector could be in an uptrend till February 2019. Are you prepared to ride the trend?

Bitcoin Continues Stellar Rise(Chart Of The Day)

Aug 10, 2017

Bitcoin hits an all-time high, is there more upside left?

5 Steps To Become Financially Independent(Outside View)

Aug 16, 2017

Ensure your financial Independence, and pledge to start the journey towards financial freedom today!

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DIVIS LABORATORIES SHARE PRICE


Aug 23, 2017 (Close)

TRACK DIVIS LABORATORIES

  • Track your investment in DIVIS LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DIVIS LABORATORIES

DIVIS LABORATORIES - SUVEN LIFE COMPARISON

COMPARE DIVIS LABORATORIES WITH

MARKET STATS